GLP-1 Receptor Agonist (Oral) Pregnancy: US label: available data in pregnant women are insufficient to evaluate a drug-associated risk of major birth defects or miscarriage; based on animal reproduction studies there may be potential risks to the fetus. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. (Note: the UK SPC captured in the bundle was for the subcutaneous injection, which states semaglutide should not be used during pregnancy and should be discontinued at least 2 months before a planned pregnancy — verify the UK oral SPC.)

Semaglutide (Oral)

Brand names: Rybelsus

Oral semaglutide is a GLP-1 receptor agonist taken as a daily tablet for type 2 diabetes (the first oral GLP-1 agonist), with weight and cardiovascular benefit.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: RYBELSUS tablets: 3 mg orally once daily for days 1 to 30 (this dosage is not effective for glycaemic control), then increase to 7 mg once daily for days 31 to 60; on day 61 or thereafter, maintain 7 mg once daily if no additional glycaemic control is needed, or increase to 14 mg once daily if additional glycaemic control is needed

Route: Oral — take on an empty stomach in the morning with water (up to 4 ounces / about 120 mL of water); do not take with other liquids; swallow whole, do not split, crush, chew or dissolve; wait at least 30 minutes before eating, drinking other beverages or taking other oral medicines

Frequency: Once daily (do not take more than one tablet per day)

Max: 14 mg once daily (RYBELSUS); 9 mg once daily (OZEMPIC tablets)

SOURCE CAVEAT: the eMC record in the fetched bundle was the Ozempic 0.25 mg SOLUTION FOR INJECTION SPC (subcutaneous, once weekly) — a route mismatch for this oral page — so it was NOT used for the dose. The dose above is from the US label for the oral tablets; the UK oral SPC (Rybelsus) must be verified. OZEMPIC TABLETS (a separate oral product on the same US label): 1.5 mg once daily for days 1 to 30 (not effective for glycaemic control), then 4 mg once daily days 31 to 60, then from day 61 maintain 4 mg or increase to 9 mg once daily if additional glycaemic control is needed. RYBELSUS and OZEMPIC tablets are NOT substitutable on a mg-to-mg basis. Do not switch between them during the initiation phase (days 1 to 30); after 30 days patients may switch (7 mg Rybelsus corresponds to 4 mg Ozempic tablets; 14 mg Rybelsus to 9 mg Ozempic tablets), starting the other product the day after discontinuing the previous one. Switching from Ozempic 0.5 mg subcutaneous injection: one week after discontinuing the injection, start Rybelsus 7 mg or 14 mg once daily (or Ozempic tablets 4 mg or 9 mg once daily). Missed dose: skip the missed dose and take the next dose the following day. Paediatric: safety and effectiveness of Rybelsus and Ozempic tablets have not been established in paediatric patients.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

US labelling (FDA)

Reference — US labelling, may differ from UK

• RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis. • Take RYBELSUS or OZEMPIC tablets orally once daily on an empty stomach in the morning with water (up to 4 ounces of water); do not take with other liquids besides water. ( 2.1 ) • Swallow tablets whole. Do not split, crush, chew or dissolve in any solution. ( 2.1 ) • After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications. ( 2.1 ) • See the Full Prescribing Information for instructions on switching between RYBELSUS and OZEMPIC tablets ( 2.3 ) and from OZEMPIC injections to RYBELSUS or OZEMPIC tablets. ( 2.4 ) Recommended Starting, …

Source: US FDA prescribing information (openFDA / DailyMed), label dated 2026-01-30. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Prior serious hypersensitivity reaction to semaglutide or to any of the excipients (serious hypersensitivity reactions including anaphylaxis and angioedema have been reported)

Side effects

Nausea (most common, incidence 5% or greater)
Abdominal pain
Diarrhoea
Decreased appetite
Vomiting
Constipation

Interactions

Insulin secretagogues (e.g. sulfonylureas) or insulin — increased risk of hypoglycaemia including severe hypoglycaemia; consider reducing the dose of the secretagogue or insulin when initiating
Other oral drugs — semaglutide delays gastric emptying and may affect absorption; consider increased clinical or laboratory monitoring for drugs with a narrow therapeutic index or that require monitoring
Levothyroxine — exposure increased by 33% (90% CI 1.25 to 1.42) when given with semaglutide tablets

Clinical monograph

How it works

It is a GLP-1 analogue (glucose-dependent insulin secretion, reduced glucagon, slowed gastric emptying, reduced appetite), co-formulated with an absorption enhancer to allow oral absorption.

Prescribing in practice

Administration is strict — take it on an empty stomach with no more than a small sip of plain water, at least 30 minutes before any other food, drink or medicine, or it is poorly absorbed.
Gastrointestinal effects are common; pancreatitis is a rare but important risk; rapid glucose improvement may transiently worsen diabetic retinopathy.
It is contraindicated in medullary thyroid carcinoma/MEN 2 history and is not for type 1 diabetes or DKA.

Monitoring

Monitor glycaemia, weight and GI tolerance; arrange eye review where retinopathy is a concern.

Counselling the patient

Take it exactly as directed: empty stomach, a small sip of water only, then wait at least 30 minutes before anything else.
Report severe or persistent abdominal pain.

Evidence & guidelines

Improves glycaemia and weight with cardiovascular benefit (PIONEER programme; NICE NG28).

Reference: NICE NG28 (Type 2 DM); PIONEER Trials (NEJM 2019); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways